Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
22 févr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
08 janv. 2024 08h00 HE
|
Xenon Pharmaceuticals Inc.
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for...
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
04 déc. 2023 16h16 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously...
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
02 déc. 2023 12h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its...
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
29 nov. 2023 22h51 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its...
Xenon Pharmaceuticals Announces Proposed Public Offering
29 nov. 2023 16h03 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has...
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
27 nov. 2023 07h00 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the...
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
09 nov. 2023 16h03 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine...
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
08 nov. 2023 16h01 HE
|
Xenon Pharmaceuticals Inc.
Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2...